moatshark My

All holdings

Angiodynamics

ANGO

Source: the SEC Form 13F filings of the managers we follow, latest for Q3 2026. How we use them

Managers holding
1
In their latest 13F (Q3 2026)
See who
Value held
$3.6m
Combined value at quarter end
Last quarter
1 bought
0 sold or trimmed
Price at Q2 ’26 end
$13.01
+14.4% in the quarter

Prices here are quarter-end prices implied by the 13F filings. Today’s price on Yahoo Finance

Share price change by quarter

+28.6%Q3 ’24
+17.7%Q4 ’24
+2.5%Q1 ’25
+5.6%Q2 ’25
+12.6%Q3 ’25
+15.0%Q4 ’25
-11.4%Q1 ’26
+14.4%Q2 ’26
Q3 ’24: +28.6%; Q4 ’24: +17.7%; Q1 ’25: +2.5%; Q2 ’25: +5.6%; Q3 ’25: +12.6%; Q4 ’25: +15.0%; Q1 ’26: -11.4%; Q2 ’26: +14.4%

Change in the quarter-end price implied by managers’ 13F filings, adjusted for stock splits. Excludes dividends.

Managers holding it, by quarter

0Q4 ’23
0Q1 ’24
1Q2 ’24
1Q3 ’24
1Q4 ’24
1Q1 ’25
1Q2 ’25
1Q3 ’25
1Q4 ’25
1Q1 ’26
1Q2 ’26
0Q3 ’26
Q4 ’23: 0; Q1 ’24: 0; Q2 ’24: 1; Q3 ’24: 1; Q4 ’24: 1; Q1 ’25: 1; Q2 ’25: 1; Q3 ’25: 1; Q4 ’25: 1; Q1 ’26: 1; Q2 ’26: 1; Q3 ’26: 0

Counts the managers on this site whose 13F for that quarter includes Angiodynamics.

Who holds it

Each manager’s latest 13F, sorted by how much of their portfolio it is. Changes are against their previous quarter.

Managers holding Angiodynamics
First Eagle Investment Management0.0%$3.6m$3.6mAdded +0.3%9 qtrs

Download the holders: CSV · JSON · Markdown

Directors buying and selling

Open-market trades by directors, officers and 10% holders over the last 12 months. How this works
From their Form 4 filings with the SEC. Grants, option exercises and shares sold to pay tax are left out.
Insider purchases and sales of Angiodynamics
Bought or soldFiling
30 Jul 2026Nighan Warren JrSVP Quality and Regulatory▼ Sold23,370$14.72$344kForm 4

About the company

Sector
Health care · Surgical & Medical Instruments & Apparatus
Incorporated in
Delaware
Financial year ends
31 May
Shares outstanding
42m at 7 Oct 2026
SEC filings
Annual reports and other filings on EDGAR

Revenue and profit

$354mMay ’14
$354mMay ’16
$262mMay ’18
$264mMay ’20
$316mMay ’22
$304mMay ’24
$320mMay ’26
May ’14: $354m; May ’15: $357m; May ’16: $354m; May ’17: $350m; May ’18: $262m; May ’19: $271m; May ’20: $264m; May ’21: $291m; May ’22: $316m; May ’23: $339m; May ’24: $304m; May ’25: $292m; May ’26: $320m
Angiodynamics revenue and net income by year
YearRevenueNet income
Year to May 2026$320m−$36.7m
Year to May 2025$292m−$34.0m
Year to May 2024$304m−$184m
Year to May 2023$339m−$52.4m
Year to May 2022$316m−$26.5m
Year to May 2021$291m−$31.5m
Year to May 2020$264m−$167m
Year to May 2019$271m$61.3m
Year to May 2018$262m$16.3m
Year to May 2017$350m$5.0m
Year to May 2016$354m−$43.6m
Year to May 2015$357m−$3.4m
Year to May 2014$354m$2.3m

From the company’s XBRL financial statements filed with the SEC, for each financial year. Gaps mean the company didn’t report that figure in a standard form.